Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss-of-function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, CYP2C19 loss-of-function alleles confer increased risks for serious adver...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Scott, S A, Sangkuhl, K, Stein, C M, Hulot, J-S, Mega, J L, Roden, D M, Klein, T E, Sabatine, M S, Johnson, J A, Shuldiner, A R
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2013
Matèries:
CPIC Update
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3748366/
https://ncbi.nlm.nih.gov/pubmed/23698643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/clpt.2013.105
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars